HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Chimeric antigen receptor modified T (CAR-T) cell therapy still has multiple difficulties in
solid tumors, such as absence of tumor specific antigens, complex immunosuppressive tumor
microenvironment, and tumor heterogeneity. In this study, investigators developed a novel
hypoxia-stimulated CAR expression system (HypoSti.CAR) that could enable CAR-T cell
effectively expand and survive in hypoxic tumor microenvironment. After accomplishment of
animal model verification, investigators conduct this clinical trial in order to assess the
in vivo safety, feasibility and efficacy of HypoSti.CAR-HER2 T cells in HER2 antigen positive
advanced solid tumors.